Skip to main content
OpenTrials
Completed

NCT Number: NCT00609102

Antioxidant Treatment of Type 2 Diabetes

This study examines whether an antioxidant taken orally will improve glucose tolerance and insulin secretion in type 2 diabetic subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Pacific Northwest Research Institute

Seattle, Washington, 98122, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects with a known diagnosis of type 2 diabetes -

Exclusion criteria

None, except known intolerance to n-acetylcysteine

-

Treatment and study plan

Placebo

Drug

one capsule BID

n-aceylcysteine

Drug

450 mgm BID

Primary outcomes

  1. Blood glucose

    Time frame: 3 months

Secondary outcomes

  1. HbA1c levels

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Nih

Registry information

Important dates

Study start
2008
Primary completion
2013
Study completion
2013
First posted
Feb 6, 2008
Registry last updated
Dec 24, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.